- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04255238
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
February 17, 2020 updated by: LG Chem
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Compared to add-on Therapy With Gemigliptin 50 mg in Combination With Metformin or Dapagliflozin 10 mg in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with Metformin or Dapagliflozin 10 mg in combination with Metformin in patients with type 2 diabetes mellitus who have inadequate glycemic control on metformin alone
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
468
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus
- Patients upper 19 years old
- Patients who had taken Metformin(≥1000mg/day) more than 8 weeks and who have inadequate blood glucose control
- Patients who have signed an informed consent themselves after receiving explanation about the clinical study
Patients who are applicable to one of the three in the following.
- Surgically infertile patients
- Postmenopausal female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation
- Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of contraceptive measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the investigational product
Exclusion Criteria:
- Patients with type 1 diabetes mellitus, Diabetic ketoacidosis, Metabolic acidosis Diabetic coma, Diabetic pre-coma
- Patients with Gestational diabetes, or secondary diabetes
- Patients with NYHA Class II~IV congestive heart failure or arrhythmia requiring treatment
- Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy
- Patients with positive Serologic results of HBsAg, HCV Ab, HIV Ab test within 4 weeks prior to Visit 1 (Screening) or at Visit 1 (Screening)
- Patients with Body Mass Index(BMI) #40 kg/m2
- Patients who are receiving intravenous iodine contrast agents within 48 hours prior to Visit 1(Screening) or planned during the clinical trial period (eg, intravenous urography, venous cholangiography, angiography, computed tomography using contrast media, etc.).
- Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)
- Patients on clinically significant dehydration, diarrhea, and vomiting at the time of Visit 1(Screening)
- Patients with pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)
- Patients with a history of alcoholism or drug addiction within 1 years prior to Visit 1(Screening)
- Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.
Patients with the outcomes of the laboratory tests performed at Visit
1(Screening) applicable to the criteria below
- Bilirubin >2 × upper limit of normal(ULN)
- AST/ALT >3 × ULN
Patients with a history of hypersensitivity reactions to the drugs below
- Dipeptidyl-peptidase4(DPP4) inhibitors
- Sodium/glucose co transport-2(SGLT-2) inhibitor
- Biguanides
- Patients who were administered the drugs below
- Patients who had been administered anti-obesity drugs within 12 weeks prior to Visit 1(Screening)
- Patients who have undergone bariatric surgery within the 1 year prior to Visit 1 (Screening) or are scheduled during the trial
- Patients with a genetic problems such as Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption)
- Female patients who are pregnant or lactating
- Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)
- Patients who are otherwise considered to be ineligible for this study on investigators' judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gemigliptin 50 mg and Dapagliflozin 10 mg
|
The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total.
- Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Other Names:
The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total.
- Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Other Names:
|
Active Comparator: Gemigliptin 50 mg and Dapagliflozin placebo
|
The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total.
- Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Other Names:
|
Active Comparator: Gemigliptin placebo and Dapagliflozin 10mg
|
The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total.
- Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Chages from baseline HbA1c at Week24
Time Frame: Baseline to Week24
|
Baseline to Week24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 30, 2020
Primary Completion (Anticipated)
May 30, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
February 2, 2020
First Submitted That Met QC Criteria
February 3, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
February 19, 2020
Last Update Submitted That Met QC Criteria
February 17, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-GLCL001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Gemigliptin 50mg
-
LG ChemCompleted
-
LG ChemCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
LG Life SciencesCompletedType 2 Diabetes MellitusKorea, Republic of
-
Seoul National University Bundang HospitalLG Life SciencesUnknownCancer | Cisplatin Adverse ReactionKorea, Republic of
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
LG Life SciencesCompletedType 2 Diabetes MellitusKorea, Republic of
-
LG Life SciencesCompleted
-
Bangkok Metropolitan Administration Medical College...CompletedDiabetic NephropathiesThailand
-
LG Life SciencesCompleted